Collectively, this data demonstrate a more potent MTA1/HIF‐1α‐targeted response to Pter/SAHA combination treatment than to single therapies both in murine prostate tumors and in PCa cell lines. The gene discussed is MTA1; the disease is prostate neoplasm.